Free Trial
NASDAQ:ALEC

Alector Q1 2024 Earnings Report

Alector logo
$2.96 -0.09 (-2.95%)
Closing price 09/30/2025 04:00 PM Eastern
Extended Trading
$2.96 +0.00 (+0.17%)
As of 09/30/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Alector Revenue Results

Actual Revenue
$15.89 million
Expected Revenue
$14.63 million
Beat/Miss
Beat by +$1.26 million
YoY Revenue Growth
N/A

Alector Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Alector's Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Alector Earnings Headlines

Alector (NASDAQ:ALEC) Stock Rating Lowered by Wall Street Zen
Brokerages Set Alector, Inc. (NASDAQ:ALEC) PT at $4.17
Is Nvidia about to Trigger Another 150X Opportunity?
Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics processing units. Legendary investor Louis Navellier believes this new invention could be even more revolutionary and mint a new wave of millionaires.tc pixel
Alector (NASDAQ:ALEC) Earns Buy Rating from BTIG Research
Alector, Inc. - Special Call
See More Alector Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email.

About Alector

Alector (NASDAQ:ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies. Alector designs its molecules to engage key immune receptors in the brain, seeking to slow or halt disease progression rather than simply address symptoms. Research and development activities are supported by state-of-the-art laboratories in North America and collaborations with academic and industry partners in Europe.

Since completing its initial public offering in 2019, Alector has expanded its clinical footprint through strategic alliances and investigator-initiated trials. The company maintains global development programs aimed at bringing the first approved immuno-neurology therapies to patients worldwide.

Alector is led by co-founder and Chief Executive Officer Dr. Arnon Rosenthal, a neuroscientist with over two decades of experience in immunology and drug discovery. The management team brings extensive backgrounds in clinical development, regulatory affairs, and commercialization, supporting Alector’s mission to transform the treatment landscape for neurodegenerative diseases.

View Alector Profile

More Earnings Resources from MarketBeat